Videos

  Clinical Conversations by Experts View all

Clinical Case-Based Learning: Virtual Tumor Board in Advanced Prostate Cancer

ESMO 2022

Latest Videos

PSMA Targeted PET Imaging of Prostate Cancer, An SNMMI Webinar - Frankis Almaguel & Michael Gorin
Predicting Efficacy of Both Nivolumab and of Nivolumab + Ipilimumab in Frontline mccRCC Patients, An Ancillary Analyses from the BIONIKK Randomized Trial - Maxime Meylan
Long-Term Outcomes in EV-301, Enfortumab Vedotin Versus Chemotherapy in Patients With Previously Treated Advanced Urothelial Carcinoma - Jonathan Rosenberg
Abemaciclib in Combination With Abiraterone Plus Prednisone in Men With High-risk mHSPC, CYCLONE 3 - Rana McKay
Biomarker Analysis to Identify Molecular Signatures Predictive of Response in the COMBAT Study - Emmanuel Antonarakis
From Science to Clinical Utility: Cxbladder Monitor - Bladder Cancer Surveillance for Patients with Urothelial Carcinoma - Tamer Aboushwareb, Neal Shore & Josh Meeks
Using Liquid Biopsies in Clinical Practice to Inform Decision Making for Prostate Cancer Care - Joshua Lang
Veterans Affair Care Program, Prostate Cancer Biorepository - Isla P. Garraway
Tumor Board Reviewing the Use of PSMA PET in Patient with Gleason 4+5=9, GG 5 Disease, Bone Scan Demonstrated Mild Uptake Prostate Cancer - Session 2 Case 1 - H Jacene, A Kibel, P Nguyen, & A Morgans
Tumor Board Reviewing the Use of PSMA PET in the Care of Patient Who Underwent Fluciclovine for Prostate Cancer - Session 1 Case 6
Tumor Board Reviewing the Use of PSMA PET in the Care of Patient with Gleason 4+5=9, GG 5 with Seminal Vesicle Invasion Prostate Cancer - Session 1 Case 5 - H Jacene, A Kibel, P Nguyen, & A Morgans
The Prostate Cancer Foundation VA Health Initiatives, Executing Precision Oncology within the VA - Matthew Rettig & Isla Garraway
Using Artificial Intelligence (AI) to Identify and Diagnose Bladder Cancer - Hikmat Al-Ahmadie & Olivier Elemento
MRI Versus Cystoscopic Staging for Newly Diagnosed Bladder Cancer, The BladderPath Trial - Nicholas James
rPFS Improvement Regardless of Mutations in Biomarker Subgroups in the Phase III PROpel Trial in First-Line Therapy for Patients with mCRPC - Fred Saad
The Intensified Treatment Landscape of Metastatic Hormone Sensitive Prostate Cancer (mHSPC) - Russell Szmulewitz
Looking forward to the SOGUG (Spanish Oncology Genito Urinary Group) Annual Meeting - Cristina Suarez & Aránzazu González del Alba
Tumor Board Reviewing the Use of PSMA PET in Prostate Cancer Gleason 4+4=8 GG 4, PI-RADS 5 Lesion, Possible Seminal Vesicle Involvement - Session 2 Case 2 - H Jacene, A Kibel, P Nguyen, & A Morgans
Tumor Board Reviewing the Use of PSMA PET in Prostate Cancer - Gleason 3+3=6 GG 1, PALB2 Mutation - Session 2 Case 3 - H Jacene, A Kibel, P Nguyen, & A Morgans
8-month PSA Outcomes of Men with Metastatic Castration-Sensitive Prostate Cancer in the PEACE-1 Phase 3 Trial - Gwenaëlle Gravis Mescam
From Science to Clinical Utility: Cxbladder Detect - Bladder Cancer Detection for Patients Who Present with Hematuria - Tamer Aboushwareb, Neal Shore & Josh Meeks

Practical Management of Bone Health and Bone Targeted Therapy in mCRPC Videos

ASCO 2022 Videos

Long-Term Outcomes in EV-301, Enfortumab Vedotin Versus Chemotherapy in Patients With Previously Treated Advanced Urothelial Carcinoma - Jonathan Rosenberg
The Intensified Treatment Landscape of Metastatic Hormone Sensitive Prostate Cancer (mHSPC) - Russell Szmulewitz
PSMA PET Scan Imaging in Prostate Cancer - Ashley Ross
CAR T and Cellular-Based Therapies - Vivek Narayan
Results of a Phase II Randomized Double Blind Trial of PF-04518600, OX40 Antibody, in Combination with Axitinib - Sarmad Sadeghi
A Novel Imaging Modality, FAP Imaging for Patients with Bladder Cancer - Vadim S. Koshkin
A Pre-Specified Gene-by-Gene Analysis of Primary and Secondary Endpoints in the MAGNITUDE Clinical Trial - Shahneen Sandhu
Multidisciplinary Care for Patients, a Book Interview - Alicia Morgans
Multidisciplinary Care Teams to Optimize Care of Patients with Bone Metastatic CRPC - Tanya Dorff
Imaging and PET Analysis as a Prognostic Tool for Lu-PSMA-617 Treatment in Patients with mCRPC - Phillip H. Kuo
Biomarker-Directed Therapy in Men with Metastatic Castration-Resistant Prostate Cancer (mCRPC) - Clara Hwang
Clinical Trial Endpoints in the Adjuvant Setting for Renal Cell Carcinoma and Urothelial Cancer - Andrea Apolo and Pavlos Msaouel
The Future of Radiopharmaceuticals in the Treatment of Prostate Cancer - Philip Kantoff
Timing and Intensity of ADT in Biochemical Recurrence - Channing J. Paller
Immunotherapy and PARP Inhibitors in Biochemical Recurrent Prostate Cancer - Alexandra Sokolova
How Does the Data from the PEACE-1, ARASENS and ENZAMET Studies Inform Clinical Practice? - Karim Fizazi
BRCAAway - a Randomized Phase 2 Trial of Abiraterone, Olaparib, or Abiraterone + Olaparib in Patients with mCRPC with DNA Repair Defects - Maha Hussain
Overall Survival Outcomes in ENZAMET (ANZUP 1304), Trial of Enzalutamide in Metastatic Hormone-Sensitive Prostate Cancer - Ian Davis
The Association of PSA Response and Overall Survival in Patients with mHSPC in the Phase 3 ARASENS Trial - Fred Saad
Long-Term Outcomes from JAVELIN Bladder 100 - Cora Sternberg
No Longer ADT Alone in Metastatic Hormone-Sensitive Prostate Cancer, The ARASENS Trial - Cora Sternberg
Theranostics in Prostate Cancer Management - The theraP Trial - Michael Hofman

AUA 2022 Videos

The Molecular Biology of Prostate Cancer - Christopher Barbieri
Women in Urologic Oncology - Anne K. Schuckman
Bladder Cancer Highlights - Stephen Williams
A Multidisciplinary Approach to Treating High-Grade Upper Tract Disease - A Case-Based Approach - Surena Matin, Jonathan Coleman, and Jean Hoffman-Censits
Antegrade Administration of Reverse Thermal Mitomycin Gel for Primary Chemoablation of Upper Tract Urothelial Carcinoma via Percutaneous Nephrostomy Tube - Katie Murray
Comparison of Dual Lumen Versus Single Lumen Flexible Ureteroscopes in Proximal Ureteral and Renal Stone Management - Rohit Bhatt
Thermal Effects of the Super-Pulse Thulium Fiber Laser During Ureteral Stone Laser Lithotripsy: An In Vivo Porcine Study - Kalon Morgan
Automated CT-based Stone Volume Determination: An Artificial Intelligence Algorithm to Calculate Kidney Stone Volume - Kalon Morgan
Comparison of Superpulse Thulium Fiber Laser vs. Holmium Laser for Ablation of Renal Calculi in an In Vivo Porcine Model - Andyshea Afyouni
Upper Tract Urothelial Carcinoma Highlights - Nima Almassi
Adjuvant Treatment for Men with Prostate Cancer with High Risk of Metastasis, the ERADICATE Study - Ashley Ross
Gender Differences in Bladder Cancer - Lauren Cooley
Adjuvant Therapy after Nephroureterectomy for High-Risk Upper Tract Urothelial Carcinoma - Sima Porten
Incorporating Genomic Testing for Prostate Cancer into Your Practice - Daniel Lin
NCCN Guidelines Update on Selection of PSMA PET Imaging Agent in Patient Selection for Lutetium-177–PSMA-617 - Oliver Sartor
BCG Unresponsive High-Risk Non-Muscle-Invasive Bladder Cancer - Seth Lerner
Treatment of Unfavorable Intermediate Risk Prostate Cancer - Ashley Ross, Jason Hafron, and Katie Murray
Mental Health and Impact on Patients with GU Malignancies - Zachary Klaassen
The Importance of Multidisciplinary Collaboration in Urology Clinics - Neal Shore
AUA Guidelines on Localized Prostate Cancer - Stephen Boorjian & James Eastham
Prostate Volume, Baseline Urinary Symptoms, and Their Association with Treatment Choice and Post-Treatment Urinary Function in Men with Localized Prostate Cancer, The CEASAR Study - Daniel Barocas
Early Triplet Combination Therapy Shows Increased Overall Survival: The ARASENS Trial - Tomasz Beer
New Orleans Restaurant Favorites - Plan Your AUA 2022 Dining Experiences - Oliver Sartor
Practice Changing Data from ARASENS - Statistically Significant Overall Survival - Fred Saad, Bertrand Tombal, and Neal Shore
ARASENS Trial Significantly Improves Overall Survival with Darolutamide in Combination with ADT and Docetaxel for Metastatic Hormone-Sensitive Prostate Cancer - Matthew Smith
Darolutamide and Survival in Metastatic Hormone-Sensitive Prostate Cancer - ARASENS Trial - Karim Fizazi

Featured Videos

Quality of Life and Patient-relevant Endpoints With Darolutamide in the ARASENS Trial - Karim Fizazi
Insights from the STAMPEDE Trial Platform - Marina Parry & Gerhardt Attard
CAR T and Cellular-Based Therapies - Vivek Narayan
The ARASENS Trial in Metastatic Hormone-Sensitive Prostate Cancer: Benefits In the Urologic Clinical Practice - Neal Shore
Women in Urologic Oncology - Anne K. Schuckman
Multidisciplinary Care for Patients, a Book Interview - Alicia Morgans
Multidisciplinary Care Teams to Optimize Care of Patients with Bone Metastatic CRPC - Tanya Dorff
Clinical Trial Endpoints in the Adjuvant Setting for Renal Cell Carcinoma and Urothelial Cancer - Andrea Apolo and Pavlos Msaouel
The Future of Radiopharmaceuticals in the Treatment of Prostate Cancer - Philip Kantoff
Bladder Cancer Highlights - Stephen Williams
APCCC 2022: First-Line Therapy for Metastatic Castration-Resistant Prostate Cancer - Evan Yu
Cancer Survivorship and PCF - Matthew Smith & Alicia Morgans
EV-103 Cohort K, Enfortumab Vedotin Monotherapy or in Combination With Pembrolizumab in Previously Untreated Cisplatin-Ineligible Patients With Locally Advanced or Metastatic Urothelial Cancer – Jonathan E. Rosenberg
An Ancillary Study of the STAMPEDE Trial Assessing the Clinical Qualification of Transcriptome Signatures for Advanced Prostate Cancer Starting ADT +/- Abiraterone Acetate and Prednisolone - Gerhardt Attard
Smarter Screening In Prostate Cancer - Sigrid Carlsson
Evaluating the Impact of Variant Histology Pathologic Diagnosis on Survival Outcomes in Patients with Upper Tract Urothelial Carcinoma - Wesley Yip
Upper Tract Urothelial Carcinoma Highlights - Nima Almassi
A Urologist's Perspective On Treatment with Darolutamide in the Metastatic Hormone Sensitive Patient - Neal Shore
Outcomes of the ARASENS Trial by Metastatic Subtype - Bertrand Tombal
Darolutamide Approved for Patients with mHSPC - Charles Ryan
The Role of Risk-Stratified Neoadjuvant Chemotherapy in Patients with Muscle-Invasive Bladder Cancer Who Are Undergoing Radical Cystectomy - Arlene O. Siefker-Radtke and Shilpa Gupta
First Standardized Framework Measuring PSMA PET/CT Response in Metastatic Castration‑Resistant Prostate Cancer - Wolfgang Fendler and Andrei Gafita
The 6th Global Summit On Precision Diagnosis and Treatment Of Prostate Cancer - Faina Shtern, The AdMe Tech Foundation
The EMBARK Study: A Phase 3 Randomized Study of Enzalutamide Plus Leuprolide and Enzalutamide Monotherapy in High-Risk Nonmetastatic Hormone-Sensitive Prostate Cancer with Rising PSA After Local Therapy - Stephen Freedland
Optimizing the Use of Radium-223 Through Multidisciplinary Collaboration - Phillip Koo
Durability of Response to Primary Chemoablation of Low-Grade Upper Tract Urothelial Carcinoma Using UGN-101 in the OLYMPUS Trial - John Gore
Management Trends & Outcomes of Patients Undergoing Radical Cystectomy for Urothelial Carcinoma, the USC Experience - Anirban Mitra
Comparative Effectiveness Of Neoadjuvant Chemotherapy In Bladder And Upper Urinary Tract Urothelial Carcinoma - Jeffrey Holzbeierlein
Preventing Recurrence of Urothelial Carcinoma in Patients with Upper Tract Carcinoma - Aditya Bagrodia
Convatec GentleCath™ Glide No-Touch Catheters - Diane Newman
Uncoated Catheters - Diane Newman
Closed Catheters Systems - Diane Newman
Treatment Sequencing with Radium-223 in Symptomatic Disease - Fred Saad
Depression, Bone Health and Exercise in Prostate Cancer - Fred Saad, Tomasz Beer & Charles Ryan
Incorporating Genomic Testing for Prostate Cancer into Your Practice - Daniel Lin
Self Intermittent Catheters Types - Diane Newman
Surveillance Guidelines for Low-Grade Ta NMIBC Often Not Followed - Stephen Williams
A Urologist's Perspective On the Integration of Lutetium Into Clinical Practices - Neal Shore
Mental Health and Impact on Patients with GU Malignancies - Zachary Klaassen
The Importance of Multidisciplinary Collaboration in Urology Clinics - Neal Shore
PARPi Combination Therapy Use in Clinical Practice - Ready for Prime-Time? - Maha Hussain and Fred Saad
Identifying Unmet Needs in the Patient Journey in Prostate Cancer - Alicia Morgans
Future Perspectives in Prostate Imaging in Developing Countries - Ronaldo Hueb Baroni
Barriers and Opportunities in Active Surveillance, HIFU, and Focal Therapy in Latin American Countries - Laurence Klotz
Microbiome Research in Bladder Cancer - Laura Bukavina
Outcomes Between Patients With and Without Prior Intravesical BCG, Who Received Immune Checkpoint Inhibitors for Advanced Urothelial Carcinoma - Rafee Talukder & Petros Grivas
The Management of High-Risk Localized Disease and Double Therapy in the mCRPC Setting - Andrey Soares
Novel Approaches in the Management of High-Risk Prostate Cancer - Ray Manneh Kopp
Evidence Supporting the Use of Urinary Catheters for Intermittent Catheterization - Diane Newman
Lessons Learned in the STAMPEDE Trial - Nicholas James
Treatment Delay Experiences Among Black and White Men with Prostate Cancer - Bhav Jain
Mechanistic Pathway Through Which Saphenous Nerve Stimulation Can Modulate Bladder Function - Paul Yoo
Developing A Novel Neuromodulation Therapy for Treating Overactive Bladder - Anne Agur
Radiotherapy Guided by PSMA PET Molecular Imaging - Juan Galvis Serrano
Preparing for Treatment with 177Lu-PSMA-617 - Kendra Harris
Administering Pluvicto™ - A Patient Shares His Treatment Experience of 177Lu-PSMA-617 - Kendra Harris and Phillip Koo
Higher Rates of Metastatic Disease on PSMA PET for Biochemical Recurrence Risk Groups, Journal Club - Christopher Wallis & Zachary Klaassen
The Performance of a Genomic Classifier Score in the Phase 3 SAKK 09/10 in Patients with Biochemical Progression - Alan Dal Pra
Shared Decision-Making vs. Physician or Patient-Directed Decisions on Patient Quality of Life and Decision Satisfaction in Metastatic Prostate Cancer - Frank Schumacher
The Role of Bladder-Sparing Trimodality Therapy - Sophia Kamran
Biological Pathways in Urothelial Carcinoma - Carissa Chu
Long-Term Safety and Durability to Non-Surgical Treatment Instillation of UGN-101, Mitomycin-Containing Reverse Thermal Gel for Low-Grade Upper Tract Urothelial Carcinoma, Journal Club - Zachary Klaassen and Christopher Wallis
Treating Women with Bladder Cancer and a Community Approach to Navigating a Diagnosis - Jeannie Hoffman-Censits & Elizabeth Guancial
The Upcoming 2022 European International Kidney Cancer Symposium - Samra Turajlic
Gemcitabine and Cisplatin as Neoadjuvant Chemotherapy in Patients with High-Grade Upper Tract Urothelial Carcinoma - Wesley Yip
Radiation Safety and the Integration of Pluvicto™ (177Lu-PSMA-617) in Treatment of mCRPC- Kendra Harris
Clinical Trial Equity in Radionuclide Treatment for Prostate Cancer - Joseph Osborne
Clinical Implementation of Pluvicto™ (177Lu-PSMA-617) - Michael Morris
The APCCC 2022 - A Hybrid Meeting April 28 - 30 - Silke Gillessen
Risk Stratification for Localized Prostate Cancer - Matthew Cooperberg
Symptoms Related to Bone Metastasis in Men Receiving Lutetium-177 PSMA-617 for Prostate Cancer - Brian Gonzalez
Pluvicto The First Targeted Radioligand Therapy for Treatment of Metastatic Castration-Resistant Prostate Cancer FDA Approved - Charles Ryan and Alicia Morgans
Molecular Biomarkers in Upper-Tract Urothelial Carcinoma - Janet Kukreja
Associations of Adverse Pathology With 20 Year Risk of Distant Metastasis and Prostate Cancer Specific Mortality - Michael Brooks
The Effect of Durvalumab and Olaparib on Prolong Progression-Free Survival As First-Line Therapy in Platinum-Ineligible Patients With Unresectable Urothelial Carcinoma - The BAYOU Study – Jonathan Rosenberg
Treatment and Survival Differences in Patients With Urothelial Vs. Nonurothelial Bladder & Upper Tract Carcinomas - Jeanny Aragon-Ching
Validating the Association of Adverse Pathology with Distant Metastasis and Prostate Cancer Mortality 20-Years After Radical Prostatectomy - Eric Klein
The Next Wave of Novel Radiopharmaceuticals - Shahneen Sandhu
Appropriate Use Criteria for PSMA PET Imaging - Hossein Jadvar
KEYNOTE-564 30-Month Follow-Up of Pembrolizumab as Post Nephrectomy Adjuvant Therapy for Patients with Renal Cell Carcinoma - Toni Choueiri
DS8201-a-U105 Trial of Trastuzumab Deruxtecan With Nivolumab in Patients With Urothelial Carcinoma – Matt Galsky
Validation of Performance of the Decipher Biopsy Genomic Classifier in Intermediate-Risk Prostate Cancer: The Phase III Randomized Trial NRG Oncology/RTOG 0126 – Jeff Michalski
Darolutamide and Survival in Metastatic Hormone-Sensitive Prostate Cancer - ARASENS Trial - Karim Fizazi
PSMA PET/CT Imaging Indications in Prostate Cancer - Phillip Koo, Neal Shore, & Oliver Sartor
Research in Biomarkers for Bladder Cancer - The BCAN Young Investigator Awards - Benjamin Miron
Quality of Life for Patients Undergoing Radical Cystectomy - Bernard Bochner
Association of Inherited Mutations in DNA Repair Genes with Localized Prostate Cancer – Kara Maxwell
Perioperative Optimization for Patients Undergoing Radical Cystectomy – Sarah Psutka
Bladder Cancer Advocacy Network's (BCAN) Young Investigator Award Program - Elizabeth Plimack
Financial Toxicity Among Patients with Bladder Cancer - Deborah Kaye
Bladder Cancer: A Practical Guide - Ashish Kamat & Peter Black
NCCN Guidelines 2022 - Prostate Cancer on Comparison of Treatment Options for Localized Disease + Local Therapies + Disease Monitoring - Zachary Klaassen and Chris Wallis
Demonstrated Underuse of Blue Light Cystoscopy for Bladder Cancer in the United States - Patrick Lewicki
Radium-223 Plus Enzalutamide versus Enzalutamide in Patients with Progressive Metastatic Castration-Resistant Prostate Cancer - Neeraj Agarwal & Ben Maughan
NCCN Guidelines On PSMA Molecular Imaging - Tanya Dorff
A Real-World Analysis of Pain Efficacy of Radium-223 Treatment Among Patients With Metastatic Castration-Resistant Prostate Cancer and Symptomatic Bone Metastases – the REASSURE Trial – Celestia Higano
Bispecific T-cell Engager (BiTE®) in Development for Treatment of Advanced Prostate Cancer - Oliver Sartor
PSMA Imaging - Is Conventional Imaging Obsolete - Steven Rowe
Management of Small Local Recurrence Low-grade Bladder Tumors with Negative Cytology - Marek Babjuk, Morgan Roupret & Wassim Kassouf
Urogynecology Controversies: Female Pelvic Medicine and Reconstructive Surgery - Briana Walton
Treatment-Related Regret Among Men With Localized Prostate Cancer Journal Club - Christopher Wallis & Zachary Klaassen
Theranostics - Taking Over Prostate Cancer Care? - Phillip H. Kuo
Understanding Physiological PSMA Biodistribution - Jeremie Calais
Trials and Tribulations in the Management of Metastatic Hormone-Sensitive Prostate Cancer - Heather Payne
The World Bladder Cancer Patient Coalition Launches Bladder Cancer Patient Survey
High Risk Prostate Cancer and Genomics - Paul Nguyen & Alan Pollack
Single-Use Disposable Cystoscopy - Roger Dmochowski, David Chaikin, & Vijay Goli
Cabazitaxel in Male Patients with Chemotherapy Pre-Treated Metastatic Germ-Cell Tumors CABA-GCT - Giulia Baciarello
Financial Toxicity in Bladder Cancer—A Mixed Methods Study of Two Diverse Patient Populations - Sumeet Bhanvadia
Real-World Data in Second-Line Treatment Progressing mCRPC – Oliver Sartor
Do Our Treatments Drive a New Resistant Mutational Phenotype? - Ana Aparicio
Antegrade Endoscopic Upper Tract Approaches - Ryan Hsi
Time Course Profile of Adverse Events With Darolutamide in the ARAMIS Trial – Christian Gratzke
Upper Tract Urothelial Carcinoma - Clinical Case Management in High-Risk Disease - Sima Porten
PSMAfore Trial - Evaluating 177Lu-PSMA-617 in Chemotherapy-Naïve mCRPC Patients – Michael Morris
Pain and Symptomatic Skeletal Events Reported in the VISION Trial – Oliver Sartor
The Association of Smoking Status with Recurrence in Patients with Predominantly High-Risk Recurrent NMIBC - Richard Matulewicz
Delayed Deterioration in Patient Quality of Life, the Impact of Darolutamide on Local Symptoms in the ARAMIS Trial – Neal Shore
STAMPEDE Analysis of Abiraterone With or Without Enzalutamide Added to Androgen Deprivation Therapy Compared to ADT Alone In High-Risk Non-Metastatic Prostate Cancer Patients– Gerhardt Attard
A Novel Sublingual Vaccine for Prevention of Recurrent Urinary Tract Infections in Women - J. Curtis Nickel
Overall Survival Results of PEACE-1 a Phase 3 Trial in Men With De Novo Metastatic Castration-Sensitive Prostate Cancer (mCSPC) – Karim Fizazi
Health-Related Quality of Life (HRQoL) From the Phase 3 VISION Study of 177Lu-PSMA-617 in Patients With Metastatic Castration-Resistant Prostate Cancer – Karim Fizazi
The Effects of Vibegron on Ambulatory Blood Pressure in Patients With Overactive Bladder - Michael A. Weber
Choice of Urinary Diversion in Patients Undergoing Radical Cystectomy - Peter Black, Jens Bedke, and Hugh Mostafid
Impact of Age on Castration Rates from The HERO Study – Michael Cookson
Risk Stratification of Upper Tract Urothelial Carcinoma - Doug Scherr
Real-World Safety and Effectiveness of Radium-223 in Japanese Patients with Castration-Resistant Prostate Cancer (CRPC) and Bone Metastasis - Beyond the Abstract
The Stakeholders in Operationalizing an Integrated PSMA Imaging and Therapies Clinic - Kendra Harris
Personalized Hormone Therapy with Post-Operative Radiation Therapy and Validation of the Decipher Genomic Classifier in SAKK 09/10 Trial - Dan Spratt and Alan Dal Pra
When to Add ADT to Early or Late Salvage Radiation - Dan Spratt
Clinical Case Discussions - "Rising PSA 18 Months Post RP and Timing of Radiotherapy" - Ashley Ross, Alan Dal Pra, and Dan Spratt
Radium-223 Treatment for Metastatic Prostate Cancer - Ila Sethi
Implications for Genetic Testing in Urothelial Cancer - Guru Sonpavde & Maria Carlo
The NCCN Guidelines on the Use of Radium-223 in Prostate Cancer - Tanya Dorff
Health-Related Quality of Life Assessment for Patients With Advanced or Metastatic Renal Cell Carcinoma in the CLEAR Trial – Bradley McGregor
The Clinical Implications of The VISION Trial, PSMA-Targeted Radiotherapy in Metastatic Prostate Cancer - Michael Morris
The OAB Clinical Care Pathway Mobile APP - Stephen Kraus
Management and Challenges of Low Grade Upper Tract Urothelial Carcinoma - Surena Matin
The Clinical Impact and Molecular Drivers of ‘Secondary’ Muscle-Invasive Bladder Cancer - BCAN New Discoveries Young Investigator Award - Eugene J. Pietzak
Phenotypic Expression of Prostate Specific Membrane Antigen (PSMA) - Evan Yu
PCORI-Funded Initiative Evidence Gaps To Guide Future Research on the Use of Active Surveillance for Prostate Cancer – M. Minhaj Siddiqu
The Management of Primary Carcinoma of The Urethra - Reza Mehrazin
18F-DCFPyL PET/CT Imaging in Patients with Suspected Recurrence of Prostate Cancer (CONDOR) Journal Club - Christopher Wallis & Zachary Klaassen
Optimal Patient Selection for Treatment with Radium-223 in mCRPC Towards Improved Overall Survival and Improved Quality of Life - Brenda Martone
Defining the Standard of Therapy for First-Line mHSPC - Lisa Horvath
Sexual Function in Women Undergoing Radical Cystectomy, BCAN New Discoveries Young Investigator Award for Patient-Centered Research - Svetlana Avulova
How I Use Jelmyto™ - Karim Chamie
177LuPSMA-617 - A New Standard of Care in the Treatment of mCRPC Based on The Phase III VISION Trial Results - Michael Morris
A Systematic Review of the Effectiveness and Toxicities of Lutetium-177-labeled PSMA-targeted Radioligand Therapy in Metastatic Castration-Resistant Prostate Cancer Journal Presentation - Christopher Wallis & Zachary Klaassen
PYLARIFY®, F 18-labeled PSMA Targeted PET Gains US FDA Approval - Michael Morris
Results From the IGCCCG Update Consortium in Metastatic Seminoma And Nonseminomatous Germ Cell Tumors – Silke Gillessen
Upper Tract Urothelial Carcinoma - Clinical Case Management – Jonathan Coleman
Assessment and Treatment of Cardiovascular Risk Factors in Veterans with Prostate Cancer - Ravi Parikh and Lova Sun
The Use of Blue Light Cystoscopy for Both Hospital and Outpatient Clinic - Yair Lotan and Daniel Parker
Real-World Evidence For Patients with mCRPC Treated with Cabazitaxel - Ronald de Wit
Apalutamide Confirms Overall Survival Benefit at 44-Months in Metastatic Castration-Sensitive Prostate Cancer - The TITAN Study - Neeraj Agarwal
Survivorship in Testicular Cancer - Mary Dunn
Practical Considerations for Administering Avelumab Maintenance in Clinical Practice - Petros Grivas and Neeraj Agarwal
Pembrolizumab in the Real-World Setting for Non-Muscle-Invasive Bladder Cancer Unresponsive to BCG - Arjun Balar
Molecular Landscape of NMIBC and Risk Factors for Progression A Lecture & Discussion - Eugene Pietzak
Facing Pelvic Pain - Elise De
Cabazitaxel is Active in Men with mCRPC with DDR Alterations - Karim Fizazi and Mihaela Aldea
Patient Selection for ADT Treatment with the Oral GnRH Antagonist in Clinical Practice - Ashley Ross
The Role and Timing of Urodynamics and Certificate in Urodynamics Virtual Course - Hashim Hashim
A Systematic Review of the Decipher® Genomic Classifier in Prostate Cancer - Ashley Ross & Daniel Spratt
Sequential Radium-223 Treatment of mCRPC That Progressed After First-Line Novel Antihormonal Therapy, A Real-World Clinical Outcomes Study - Oliver Sartor
Cabozantinib in Combination with Atezolizumab in Metastatic Castration-Resistant Prostate Cancer: COSMIC-021 - Neeraj Agarwal
Advances from 2020 in the Management of Muscle Invasive Non-Metastatic Bladder Cancer - Bernard Bochner
Surgical Simulator for Laparoscopic Partial Nephrectomy for Renal Cell Carcinoma - Gonzalo Vitagliano
NCCN Guidelines Updated for Prostate Cancer M1 Systemic Therapy Based Upon The CARD Trial - Tanya Dorff
The Accidental Journey of Shepherding PSMA PET Imaging in Prostate Cancer to the Clinic in the United States - Thomas Hope
Clinical Implications of the Study Findings from the Radiotherapy Adjuvant Versus Early Salvage ((TROG 08.03/ANZUP RAVES) Trial - Andrew Kneebone and Declan Murphy
Operationalizing Genomic Testing for Clinical Practice In Prostate Cancer - Jason Hafron
The Progress and Promise of Prostate Cancer Treatments in 2020 - Charles Ryan & Alicia Morgans
Nadofaragene Firadenovec for BCG Unresponsive NMIBC - Girish Kulkarni
68Ga-PSMA-11 Joins FDA-Approved Tools for Management of Prostate Cancer - Thomas Hope
Racial Differences in Genomic Profiling in Prostate Cancer - Brandon Mahal
Overall Survival Data from the Global, Phase 3 ARAMIS Trial in Men with Non Metastatic Castration-Resistant Prostate Cancer (nmCRPC) - Karim Fizazi
Changing the Standard of Care in Prostate Cancer with Advances in Nuclear Medicine, PET and Theranostics Symposium - Rob Flavell
Implications for Reducing Disparities in Muscle-Invasive Bladder Cancer - Samuel Washington III
Interim Results from AMG 160 a half-life extended (HLE), PSMA-targeted, bispecific T-cell engager (BiTE®) immune therapy for metastatic castration-resistant prostate cancer (mCRPC) - Ben Tran
An Expert Discussion on Gleason 6 (Grade Group 1) Prostate Cancer - Scott Eggener 
Treatment Considerations For Disease Progression After Combination Therapy in mCRPC - Alicia Morgans
ESMO 2020 Expert Clinical Conversation on Prostate Cancer - Oliver Sartor
The Role of FoundationOne® Liquid CDx in mCRPC - Oliver Sartor
The Dynamic Advancements in Personalized Treatments for Metastatic Urothelial Cancer - Andrea Apolo
DNA Repair and PARP Inhibitor Therapy in Prostate Cancer - Veda Giri, Patrick Pilié, and Arpit Rao
Results of the SUO CTC Phase III Nadofaragene Firadenovec Trial for BCG Unresponsive NMIBC - Colin Dinney
PSMA-directed Therapy - Scott Tagawa and Michael Morris
JAVELIN Bladder 100: Results of First-line Maintenance Therapy Plus Best Supportive Care Demonstrates Significant Prolonged OS in Advanced Urothelial Cancer - Cora Sternberg
Therapeutic Options for Patients with Metastatic Hormone-Sensitive Prostate Cancer - Evan Yu
Neoadjuvant Vs. Adjuvant Chemotherapy in Upper Tract Urothelial Carcinoma - Alison Birtle & Surena Matin
A Discussion on Implementing the Treatment of Non-Metastatic Muscle-Invasive Bladder Cancer AUA/ASCO/ASTRO/SUO Guidelines - Sam Chang
Blue Light Cystoscopy with Cysview® & Adjuvant Perioperative Chemotherapy for Nonmuscle-Invasive Bladder Cancer - Sia Daneshmand & Trinity Bivalacqua
Improving and Optimizing Transurethral Resection of Bladder Tumor (TURBT) Outcomes - Hugh Mostafid
In His Own Voice: His 15-Year Journey with Advanced Prostate Cancer - Steve Poggi
A Debate on The Management of BCG Unresponsive - Cystectomy Ineligible Bladder Cancer Patients: Pembrolizumab Vs. Nadofaragene Firadenovec - Arjun Balar & Peter Black
HERO Phase III Trial: Results Comparing Relugolix, an Oral GnRH Receptor Antagonist Vs. Leuprolide Acetate for Advanced Prostate Cancer - Neal Shore
Rucaparib, A PARP Inhibitor For The Treatment of Metastatic Castration-Resistant Prostate Cancer (mCRPC) - Wassim Abida
Clinical Understanding of PARP Inhibitors in Prostate Cancer - Elena Castro, Wassim Abida, and Karen Knudsen
IMbassador250: A Study of Atezolizumab in Combination with Enzalutamide in Men with Metastatic Castration-Resistant Prostate Cancer (mCRPC) - Christopher Sweeney
Implications of the Bacillus Calmette-Guérin (BCG) Shortage - Joshua Meeks
Outcomes from The PROCEED Registry: Survival of African-American and Caucasian Men After Sipuleucel-T Immunotherapy - Oliver Sartor
In Pursuit of Patient-Centered Care - Karen Knudsen
Making Your Treatment Decision - Prostate Cancer Patient Interview with Andy Schwartz
Bone Health and Osteoclast Targeted Therapies in Advanced Prostate Cancer - Matthew Smith
NCCN Localized Prostate Cancer Patient Treatment Considerations During the COVID-19 Pandemic - Edward M. Schaeffer
NCCN Metastatic Castration-Resistant Prostate Cancer Patient Treatment Considerations During the COVID-19 Pandemic - Edward M. Schaeffer and Alicia Morgans
Prolonging Overall Survival in Men with Non-metastatic Castration Resistant Prostate Cancer ARAMIS Trial - Neal Shore
The ORIOLE Trial Results Discussed: Outcomes of Observation vs SABR for Oligometastatic Prostate Cancer - Phuoc T. Tran
Moving the Field Forward, Upper Tract Urothelial Carcinoma, The POUT Study - Alison Birtle
Implementing Prostate Cancer Working Group 3 Criteria in Clinical Trials- Michael Morris and Lawrence Schwartz
CARD Study Demonstrates Cabazitaxel Improves Pain and Health-Related Quality of Life Analysis in Patients with mCRPC - Karim Fizazi
A New Era In Systemic Therapies, Pembrolizumab for High Risk Non-Muscle Invasive BCG-Refractory Patients - Arjun Balar
The VISION Trial: Radionuclide Therapy Plus Standard Therapy for Metastatic Castration Resistant Prostate Cancer - Oliver Sartor and Michael Morris
First-line Therapy Options for Metastatic Renal Cell Carcinoma - Tian Zhang
A Study Evaluating Optimal Use of Radioactive Drugs for Prostate Cancer Therapy - Misha Beltran
Prospective, Real-World Data Analysis Showed Additional Overall Survival Benefit with Sipuleucel-T in African American Patients – Oliver Sartor
Genetic Counseling in Prostate Cancer - Brittany Szymaniak
Darolutamide Treated Patients Maintained Quality of Life in ARAMIS Trial - Fred Saad
Clinical Trials: Another Treatment Option for Patients - Tom Farrington
Radium-223 in Clinical Practice - Phillip J. Koo
Treatment Approaches in Metastatic Hormone Sensitive Prostate Cancer (mHSPC)- Alicia Morgans
Challenges in the Diagnosis and Treatment of UTUC - Peter Black
Theranostic Approaches for Advanced Prostate Cancer - Michael Hofman
Immunotherapy Across Genitourinary Malignancies - James Gulley
Optimizing ADT in Prostate Cancer Patients - Tom Keane
Blue Light Cystoscopy for Diagnosis of Bladder Cancer - A Journal Club Review by Badrinath Konety
High Grade Non-Muscle Invasive Bladder Cancer and BCG Refractory Patient - Josh Meeks
CARMENA: Practice Changing Strategies for Kidney Cancer
Survival Outcomes in Metastatic Castration-Resistant Prostate Cancer (mCRPC) for Black versus White Men-Susan Halabi
Updates on Health-Related Quality-of-Life (HRQoL) analyses in GU Oncology - Cora Sternberg
Nocturia in the Aging Patient, Assessment and Treatment- Susann Varano
Genetic Evaluation and Counseling in Prostate Cancer Treatment - Interview with Heather Cheng
The State of Nuclear Medicine in the Treatment of Prostate Cancer - Interview with Oliver Sartor
Update on Bladder Cancer, Current Trials and Treatments - Bishoy Faltas
Dedication to Multidisciplinary Management of GU Oncology - Alex Kutikov
Clinical Implications of the Abi Race Study: Interview with Dan George
Imaging Modality and Recommendations Included in RADAR 3: Interview with Phillip Koo
Personalization of Therapy to Optimize Outcomes for Men with Prostate Cancer - Interview with Felix Feng
The Men’s Eating and Living (MEAL) Study, Diet Intervention in Men on Active Surveillance for Prostate Cancer - Interview with J. Kellogg Parsons
Geriatric Assessment of Men with Prostate Cancer - Alicia Morgans
New Concepts in ADT- Thomas Keane
Advances in Bladder Cancer - Systemic Therapies Including Immunotherapy - Petros Grivas
nmCRPC - Early Treatment Leading to Favorable Outcomes - Fred Saad.
Defining Bladder Health - Ariana Smith
A Revolutionizing Time in Immuno-Oncology for Bladder Cancer - Neal Shore
Meeting an Unmet Need in the Nonmetastatic Castration Resistant Prostate Cancer Patient Population - Maha Hussain
Neoadjuvant Therapy for Men with High Risk Disease Prior to Prostatectomy - Mary-Ellen Taplin

13th Uro-Oncology Meeting - São Paulo, Brazil

Localized Prostate Cancer

The Molecular Biology of Prostate Cancer - Christopher Barbieri
DNA Repair Genes Associated With Localized Prostate Cancer, Journal Club - Christopher Wallis & Zachary Klaassen
The Role of Imaging Before and After Diagnosis of Localized Prostate Cancer - Masoom Haider
Deciding Against Active Surveillance: How Genomic Testing Impacted Treatment Decision-Making Among a Predominantly African American Population - Peter Gann and Adam Murphy
How Genomic Testing Impacts NCCN Risk Classification of Black Men with Low and Intermediate Risk Prostate Cancer - Andrew Winer
The ENACT Trial: Ezalutamide Monotherapy plus Active Surveillance vs Active Surveillance Alone in Patients with Low-Risk or Intermediate-Risk Prostate Cancer - Neal Shore
LuTectomy, a Single-Arm Study of the Dosimetry, Safety, and Potential Benefit of 177Lu-PSMA-617 Prior to Radical Prostatectomy - Declan Murphy & Renu Eapen
Incorporating Genomic Testing for Prostate Cancer into Your Practice - Daniel Lin
Genomic Risk Classification in Localized Prostate Cancer - Matthew Cooperberg
Prostate Volume, Baseline Urinary Symptoms, and Their Association with Treatment Choice and Post-Treatment Urinary Function in Men with Localized Prostate Cancer, The CEASAR Study - Daniel Barocas
Barriers and Opportunities in Active Surveillance, HIFU, and Focal Therapy in Latin American Countries - Laurence Klotz
Active Surveillance for Patients With Intermediate-Risk Prostate Cancer - Stacy Loeb
Novel Approaches in the Management of High-Risk Prostate Cancer - Ray Manneh Kopp
The Benefit of ADT Treatment Intensification with Radiotherapy for Men with Localized Prostate Cancer, Journal Club - Christopher Wallis & Zachary Klaassen
Treatment Delay Experiences Among Black and White Men with Prostate Cancer - Bhav Jain
Risk Stratification for Localized Prostate Cancer - Matthew Cooperberg
Associations of Adverse Pathology With 20 Year Risk of Distant Metastasis and Prostate Cancer Specific Mortality - Michael Brooks
Validating the Association of Adverse Pathology with Distant Metastasis and Prostate Cancer Mortality 20-Years After Radical Prostatectomy - Eric Klein
AI-Derived Digital Pathology-Based Biomarker To Predict the Benefit of ADT in Localized Prostate Cancer – Dan Spratt
AI-derived Digital Pathology-Based Biomarkers in Localized Prostate Cancer - Felix Feng
Association of Inherited Mutations in DNA Repair Genes with Localized Prostate Cancer – Kara Maxwell
NCCN Guidelines 2022 - Prostate Cancer on Comparison of Treatment Options for Localized Disease + Local Therapies + Disease Monitoring - Zachary Klaassen and Chris Wallis
Treatment-Related Regret Among Men With Localized Prostate Cancer Journal Club - Christopher Wallis & Zachary Klaassen
High Risk Prostate Cancer and Genomics - Paul Nguyen & Alan Pollack
NCCN Prostate Cancer Clinical Practice Guidelines on Risk Stratification for Clinically Localized Prostate Cancer – Christopher Wallis & Zachary Klaassen
Improving the Quality of Care for Men in Michigan With Prostate Cancer, the MUSIC Collaborative, a Focus on the G-MINOR and G-MAJOR Trials – Todd Morgan
Personalized Hormone Therapy with Post-Operative Radiation Therapy and Validation of the Decipher Genomic Classifier in SAKK 09/10 Trial - Dan Spratt and Alan Dal Pra
When to Add ADT to Early or Late Salvage Radiation - Dan Spratt
Clinical Case Discussions - "Rising PSA 18 Months Post RP and Timing of Radiotherapy" - Ashley Ross, Alan Dal Pra, and Dan Spratt
Prostate Cancer Screening and Shared Decision Making in the Veterans Health Administration - Stacy Loeb
PCORI-Funded Initiative Evidence Gaps To Guide Future Research on the Use of Active Surveillance for Prostate Cancer – M. Minhaj Siddiqu
Prostate Cancer Modeling: The CISNET Prostate Group - Ruth Etzioni
A Systematic Review of the Decipher® Genomic Classifier in Prostate Cancer - Ashley Ross & Daniel Spratt
Prostate Active Surveillance Study (PASS) - Daniel Lin
How Can We Accelerate Clinical Trial Accrual in Localized Prostate Cancer? - Brian F. Chapin
An Expert Discussion on Gleason 6 (Grade Group 1) Prostate Cancer - Scott Eggener 
DASL-HiCAP (ANZUP1801): The Impact of Darolutamide on Standard Therapy for Localized Very High-risk Cancer of the Prostate - Christopher Sweeney
The Role of Neoadjuvant Therapy for Patients with Localized Prostate Cancer - Rana R. McKay
Active Surveillance for Low-Risk Prostate Cancer - Laurence Klotz and Peter Carroll
Study of Baseline PSA Screening of Men (45 years old) - Peter Albers
Radiation Therapy Advances and Technology Overview - Daniel Spratt
Epidemiologic Outcomes of Prostate Cancer Patients Undergoing Active Surveillance - Sigrid Carlsson
Exercise vs. Usual Care Among Men Opting for Active Surveillance for Prostate Cancer - June Chan
Increasing Rates of Active Surveillance as the Standard of Care in Men with Low Risk Prostate Cancer- Matthew Cooperberg
ProVent Trial for Newly Diagnosed Prostate Cancer - Benjamin Lowentritt
Engagement in Long-Term Physical Activity and Lowering the Risk of Advanced Prostate Cancer - Lorelei Mucci
Focal Therapy: Ready or Not - Herbert Lepor
EXTEND, Phase 2 Trial Evaluating the Safety and Efficacy of Exercise Training in Men with Hormone Naïve Prostate Cancer - Mike Harrison
Long-Term Outcomes of Active Surveillance for Prostate Cancer - Interview with Sigrid Carlsson
The Men’s Eating and Living (MEAL) Study, Diet Intervention in Men on Active Surveillance for Prostate Cancer - Interview with J. Kellogg Parsons
Active Surveillance: Who is the Right Patient? - Matt Cooperberg

Prostate cancer genomic classifier Videos

PORTOS as a Predictive Biomarker to Help Personalize Radiotherapy Dose in the Postoperative Setting, in the SAKK 09/10 Trial - Alan Dal Pra
Insights from the STAMPEDE Trial Platform - Marina Parry & Gerhardt Attard
The Molecular Biology of Prostate Cancer - Christopher Barbieri
An Ancillary Study of the STAMPEDE Trial Assessing the Clinical Qualification of Transcriptome Signatures for Advanced Prostate Cancer Starting ADT +/- Abiraterone Acetate and Prednisolone - Gerhardt Attard
Adjuvant Treatment for Men with Prostate Cancer with High Risk of Metastasis, the ERADICATE Study - Ashley Ross
Rationale for the Use of Decipher RP Genomic Classifier to Inform Treatment - Ashley Ross
The Use of the Decipher Biopsy Test Prior to Prostatectomy - Ashley Ross
Decipher Biopsy and Decipher for Prostatectomy in Clinical Practice- Ashley Ross
Treatment of Unfavorable Intermediate Risk Prostate Cancer - Ashley Ross, Jason Hafron, and Katie Murray
The Benefit of ADT Treatment Intensification With Radiotherapy in Localized Prostate Cancer – Dan Spratt and Amar Kishan
The Conundrum of Systemic Salvage Therapy at the Time of Salvage Radiation Therapy - Brandon Mahal
The Performance of a Genomic Classifier Score in the Phase 3 SAKK 09/10 in Patients with Biochemical Progression - Alan Dal Pra
Validation of Performance of the Decipher Biopsy Genomic Classifier in Intermediate-Risk Prostate Cancer: The Phase III Randomized Trial NRG Oncology/RTOG 0126 – Jeff Michalski
The Impact of Decipher Biopsy Testing on Clinical Outcomes in Localized Prostate Cancer – Randy A. Vince Jr.
High Risk Prostate Cancer and Genomics - Paul Nguyen & Alan Pollack
Personalized Hormone Therapy with Post-Operative Radiation Therapy and Validation of the Decipher Genomic Classifier in SAKK 09/10 Trial - Dan Spratt and Alan Dal Pra
When to Add ADT to Early or Late Salvage Radiation - Dan Spratt
Clinical Case Discussions - "Rising PSA 18 Months Post RP and Timing of Radiotherapy" - Ashley Ross, Alan Dal Pra, and Dan Spratt
Prognostic Utility of Decipher® Prostate Genomic Classifier in the SAKK 09/10 Phase III Trial - Alan Dal Pra
A Systematic Review of the Decipher® Genomic Classifier in Prostate Cancer - Ashley Ross & Daniel Spratt
Validation of a Prognostic Genomic Classifier in Salvage Radiotherapy Prostate Cancer from a Prospective Randomized Trial - Felix Feng
Data from the RTOG 9601 Study: Treating Prostate Cancer Patients with Low-Volume Disease - Daniel Spratt

Bladder Cancer Videos

From Science to Clinical Utility: Cxbladder Monitor - Bladder Cancer Surveillance for Patients with Urothelial Carcinoma - Tamer Aboushwareb, Neal Shore & Josh Meeks
Using Artificial Intelligence (AI) to Identify and Diagnose Bladder Cancer - Hikmat Al-Ahmadie & Olivier Elemento
MRI Versus Cystoscopic Staging for Newly Diagnosed Bladder Cancer, The BladderPath Trial - Nicholas James
From Science to Clinical Utility: Cxbladder Detect - Bladder Cancer Detection for Patients Who Present with Hematuria - Tamer Aboushwareb, Neal Shore & Josh Meeks
A Novel Imaging Modality, FAP Imaging for Patients with Bladder Cancer - Vadim S. Koshkin
Women in Urologic Oncology - Anne K. Schuckman
Bladder Cancer Highlights - Stephen Williams
Bladder Cancer in the Older Adult Population: Special Considerations - Tullika Garg
Highlighting 25 Years of the International Bladder Cancer Network (IBCN) - Barton Grossman
Gender Differences in Bladder Cancer - Lauren Cooley
Advances in Treatment Options for BCG Unresponsive CIS and Papillary Non-Muscle Invasive Bladder Cancer - QUILT 3.032 - Sam Chang
Management Trends & Outcomes of Patients Undergoing Radical Cystectomy for Urothelial Carcinoma, the USC Experience - Anirban Mitra
Comparative Effectiveness Of Neoadjuvant Chemotherapy In Bladder And Upper Urinary Tract Urothelial Carcinoma - Jeffrey Holzbeierlein
Preventing Recurrence of Urothelial Carcinoma in Patients with Upper Tract Carcinoma - Aditya Bagrodia
Surveillance Guidelines for Low-Grade Ta NMIBC Often Not Followed - Stephen Williams
Microbiome Research in Bladder Cancer - Laura Bukavina
Realities of Bladder Cancer In Women - Sima Porten, Kristen Scarpato, Svetlana Avulova & Anne Schuckman
Busting Common Myths Regarding Bladder Preservation for Muscle Invasive Bladder Cancer - Nick James & Ananya Choudhury
Urethral Recurrence after Radical Cystectomy for Bladder Cancer - Ekaterina Laukhtina
The Role of Bladder-Sparing Trimodality Therapy - Sophia Kamran
Biological Pathways in Urothelial Carcinoma - Carissa Chu
Treating Women with Bladder Cancer and a Community Approach to Navigating a Diagnosis - Jeannie Hoffman-Censits & Elizabeth Guancial
Comparative Effectiveness of Radical Cystectomy and Trimodality Therapy for Muscle-Invasive Bladder Cancer – Boris Gershman
Research in Biomarkers for Bladder Cancer - The BCAN Young Investigator Awards - Benjamin Miron
Quality of Life for Patients Undergoing Radical Cystectomy - Bernard Bochner
Role of Blue Light Cystoscopy in Detecting Invasive Bladder Tumor - Sia Daneshmand
Perioperative Optimization for Patients Undergoing Radical Cystectomy – Sarah Psutka
Mucosal Differences in The Bladder - Molly Ingersoll
Translational Research in Bladder Cancer, A BCAN Young Investigator - Phillip Abbosh
Bladder Cancer Advocacy Network's (BCAN) Young Investigator Award Program - Elizabeth Plimack
Financial Toxicity Among Patients with Bladder Cancer - Deborah Kaye
Bladder Cancer: A Practical Guide - Ashish Kamat & Peter Black
Urologists, You’ll Never Walk Alone! - Gianluca Giannarini
Systemic Therapies in Advanced Bladder Cancer - Noah Hahn
Management of Small Local Recurrence Low-grade Bladder Tumors with Negative Cytology - Marek Babjuk, Morgan Roupret & Wassim Kassouf
The World Bladder Cancer Patient Coalition Launches Bladder Cancer Patient Survey
Financial Toxicity in Bladder Cancer—A Mixed Methods Study of Two Diverse Patient Populations - Sumeet Bhanvadia
The Association of Smoking Status with Recurrence in Patients with Predominantly High-Risk Recurrent NMIBC - Richard Matulewicz
Value Based Care in Surveillance of Non-Muscle Invasive Bladder Cancer – Stephen Williams
ctDNA Guiding Adjuvant Immunotherapy in Urothelial Carcinoma Journal Club – Christopher Wallis & Zachary Klaassen
Immunotherapy Treatments Across the Spectrum of Urothelial Cancer Stages - Bishoy Faltas
Bladder-Sparing Treatment Options for Muscle-Invasive Bladder Cancer – Andrea Necchi
The Clinical Impact and Molecular Drivers of ‘Secondary’ Muscle-Invasive Bladder Cancer - BCAN New Discoveries Young Investigator Award - Eugene J. Pietzak
The Management of Primary Carcinoma of The Urethra - Reza Mehrazin
Germline and Somatic Interactions in Bladder Cancer - Bishoy Faltas
Sexual Function in Women Undergoing Radical Cystectomy, BCAN New Discoveries Young Investigator Award for Patient-Centered Research - Svetlana Avulova
Pembrolizumab in Combination With Gemcitabine and Concurrent Hypofractionated Radiation Therapy As Bladder Sparing Treatment for Muscle-Invasive Bladder Cancer - Arjun Balar
A Study to Improve the Diagnosis of Bladder Cancer - BladderPath Study - Jim Catto & Gary Steinberg
Update on Urine Markers for Hematuria and Bladder Cancer - Yair Lotan
Molecular Landscape of NMIBC and Risk Factors for Progression A Lecture & Discussion - Eugene Pietzak
Circulating Tumor DNA - Guiding Treatment Decisions in Bladder Cancer - Lars Dyrskjøt
Advances from 2020 in the Management of Muscle Invasive Non-Metastatic Bladder Cancer - Bernard Bochner
EAU Guidelines on Non-Muscle-Invasive Bladder Cancer 2020 Update - Marek Babjuk
DNA Based Markers in High-risk Non-Muscle Invasive BCG Unresponsive Bladder Cancer - Alexander Wyatt
Pembrolizumab in High-Risk, BCG Unresponsive Non-Muscle Invasive Bladder Cancer - Arjun Balar
A Patient Perspective on High-Risk Non-Muscle Invasive BCG Unresponsive Bladder Cancer- Karen Sachse
How to Define Treatment Failure After BCG Treatment for Nonmuscle-Invasive Bladder Cancer - Peter Black
High-Risk Non Muscle-Invasive BCG Unresponsive Bladder Cancer - Molecular Subtypes - Woonyoung Choi
Vicineum for High-Risk Non-Muscle-Invasive BCG Unresponsive Bladder Cancer - Rian J. Dickstein
The Role of the PD-L1 Checkpoint in BCG Resistance - Max Kates
Variant Histology Urothelial Carcinoma: A Patient Case - Makarand Khochikar
T2 N0 M0 High-grade Urothelial Carcinoma Patient Case Study with Cushingoid Features Undergoing Radical Cystectomy in Neobladder - Makarand Khochikar
Clinically Node Positive Bladder Cancer and The Timing of Surgery - Neema Navai
The Management of Bladder Cancer During Pregnancy - Makarand Khochikar
Adherence to Guidelines-Based Management of Non-Muscle Invasive Bladder Cancer Among Society of Urologic Oncology (SUO) Members - Justin T. Matulay
Urinary Diversion in Women Following Radical Cystectomy - Renu Eapen
Radical Cystectomy and The Importance of Oncological Concepts in Surgical Approach - Rafael Sanchez Salas
T2 N0 M0 Muscle-invasive Bladder Cancer Patient Case - Makarand Khochikar
Results of the SUO CTC Phase III Nadofaragene Firadenovec Trial for BCG Unresponsive NMIBC - Colin Dinney
Blue Light Cystoscopy with Cysview®: Tips and Tricks - Anne Schuckman
The RESECT Study: Improving Quality in TURBT Surgery - Veeru Kasivisvanathan
AUA Guidelines Case-Based Panel Discussion: Bladder Cancer (Non-muscle and Muscle Invasive) - Joshua Meeks and Sima Porten
Macro and Microeconomics of Blue Light Cystoscopy with CYSVIEW® in Non-Muscle Invasive Bladder Cancer - Stephen Williams
A Discussion on Implementing the Treatment of Non-Metastatic Muscle-Invasive Bladder Cancer AUA/ASCO/ASTRO/SUO Guidelines - Sam Chang
Improving and Optimizing Transurethral Resection of Bladder Tumor (TURBT) Outcomes - Hugh Mostafid
Treatment Options for Bacillus Calmette-Guérin (BCG) Refractory Bladder Cancer Disease - Wassim Kassouf
Role of Blue Light Cystoscopy in Bladder Cancer Management - Trinity Bivalacqua
Bladder Preservation Protocols for Muscle-Invasive Urothelial Carcinoma - Arjun Balar
Weathering the Current BCG Shortage Crisis - Michael O’Donnell
Blue Light Cystoscopy with Cysview for Management of Non Muscle Invasive Bladder Cancer - Joshua Meeks
Implications of the Bacillus Calmette-Guérin (BCG) Shortage - Joshua Meeks
Improving Research and Clinical Care, Bladder Cancer in Women - Jean Hoffman-Censits
Current and Emerging Therapies for Non-Muscle Invasive Bladder Cancer after BCG - Chris Wallis & Zach Klaassen
Phase III Nadofaragene Firadenovec for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer - Joshua J. Meeks
Research and Clinical Practice Strategies Due to the BCG Shortage - Sam S. Chang
Bladder Cancer Research That Impacts Urology Clinical Practice - Josh Meeks
The Benefits of Early Recovery After Radical Cystectomy (ERAS) Protocols - Sima Porten
The BCG Shortage - What To Do In This Setting - Joshua Meeks
Advancements in BCG Unresponsive Bladder Cancer: Highlights from the 2019 SUO Meeting - Joshua Meeks
A New Era In Systemic Therapies, Pembrolizumab for High Risk Non-Muscle Invasive BCG-Refractory Patients - Arjun Balar
Utilizing Change Management for Successful Implementation of Blue light cystoscopy (BLC™) - Rebecca Roe
Evaluation of Cxbladder and Adjudication of Atypical Cytology and Equivocal Cystoscopy - Badrinath Konety
Guided Imagery for Urologic Surgery - Sima Porten
Consensus Statement on Flexible Blue Light Cystoscopy (BLC™) with Cysview® - Yair Lotan
Comparative Analyses of Costs and Survival Between Radical Cystectomy and Trimodal Therapy - Stephen Williams
Blue Light Cystoscopy with CYSVIEW: Improving Detection Rates of Bladder Cancer in the Clinic - Yair Lotan
Blue Light Cystoscopy (BLC™): What Urologist Want to Know - Anne Schuckman
Toxicity Management with Checkpoint Inhibitor Therapy - Thomas Powles
Bladder Cancer in Women - Morgan Roupret
BCG Shortage An Update - Jonathan Rubenstein
The Role of the Surgeon in the Treatment of Bladder Cancer - Jens Bedke
Immunotherapy in the Peri-Operative Setting for Bladder Cancer - Thomas Powles
What is New on Bladder Cancer Treatment: ASCO GU 2019? - Josh Meeks
ERAS in Bladder Cancer - Sia Daneshmand
The State of Immunotherapy in Bladder Cancer - Thomas Powles
Bladder Cancer in Women: Improving Diagnosis and Treatment - Jean Hoffman-Censits
Optimal Surgical Approaches in Cystectomy - Piyush Agarwal
Improving Outcomes in Bladder Cancer - Arnulf Stenzl
The Role of the Surgeon in the Management of Metastatic Bladder Cancer - Brant Inman
Radical Cystectomy vs Trimodal Therapy for Patients With Localized Muscle-Invasive Bladder Cancer - Stephen B Williams
Defining BCG-Unresponsive and The Pathway to Clinical Trials in Treating NMIBC - Ashish Kamat
BCG Shortage 2019: Managing Through Treatment and Reimbursement Issues - Neal Shore, Ashish Kamat, and Jonathan Rubenstein
2019 BCG Shortage-Perspectives from Josh Meeks
Blue Light Cystoscopy with Cysview® in the Surveillance of Bladder Cancer - Sia Daneshmand
The Importance of TURBT and the Benefits of Enhanced Cystoscopy - Sima P. Porten
Efficacy and Safety of Flexible BLC with Cysview® in the Surveillance of Bladder Cancer - Sia Daneshmand
Patient Reported Outcomes in the Use of Blue Light Cystoscopy in the Surveillance of Bladder Cancer - Angela B. Smith
Evolution of Technology and Technique in Bladder Cancer - Ashish Kamat
Immuno-Oncology in Bladder Cancer: The Urologist's Role - Noah Hahn
Is There an Optimal TURBT Technique and the Color War? - Ashish Kamat
Keynote-057 Trial for High-Risk Non-Muscle Invasive Bladder Cancer - Evan Yu
Is There Still a Role for Chemotherapy in Bladder and Prostate Cancer - Maria De Santis
Immunotherapy in Bladder Cancer - Arjun Balar
High Grade Non-Muscle Invasive Bladder Cancer and BCG Refractory Patient - Josh Meeks
Update on Bladder Cancer, Current Trials and Treatments - Bishoy Faltas
CARMENA in mRCC and Surgical Management Cases in Bladder Cancer from ASCO 2018 - Tom Keane
Updates in Advanced Urothelial Carcinoma - Highlights from ASCO 2018 - Petros Grivas
FDA ALERT: Efficacy Issue Identified in Some Patients Taking Pembrolizumab or Atezolizumab as Monotherapy to Treat Advanced Urothelial Cancer - Petros Grivas
Update in Immuno-Oncology in Bladder Cancer - Arjun Balar
Journey from Oncologist to Cancer Survivor and Patient Advocate - Burton Needles
Setting the Stage for the BCG Unresponsive Population - Interview with Ashish Kamat
Helping Patients Cope after Major Interventions for Bladder Cancer Therapy
The Changing Landscape in Advanced Bladder Cancer - Tom Keane
Advances in Bladder Cancer - Systemic Therapies Including Immunotherapy - Petros Grivas
Minimizing Treatment Burden and Biomarkers in Bladder Cancer - Badrinath Konety
A Revolutionizing Time in Immuno-Oncology for Bladder Cancer - Neal Shore
Enhanced Recovery After Surgery (ERAS) for Radical Cystectomy: History, Rationale and Programmatic Implementation - Thomas Guzzo
Treatment Options for Bladder Cancer: Bringing Life to Years of Sparse Options - Guru Sonpavde
Enhanced Recovery After Surgery (ERAS) Radical Cystectomy and Urinary Diversion- Ashish Kamat

Advanced Bladder Cancer Videos

Long-Term Outcomes in EV-301, Enfortumab Vedotin Versus Chemotherapy in Patients With Previously Treated Advanced Urothelial Carcinoma - Jonathan Rosenberg
EV-201 Enfortumab Vedotin After PD-1 or PD-L1 Inhibitors in Cisplatin-Ineligible Patients With Advanced Urothelial Carcinoma Journal Club – Christopher Wallis & Zachary Klaassen
EV-103 Cohort K, Enfortumab Vedotin Monotherapy or in Combination With Pembrolizumab in Previously Untreated Cisplatin-Ineligible Patients With Locally Advanced or Metastatic Urothelial Cancer – Jonathan E. Rosenberg
Molecular Subtyping and Neoadjuvant Chemotherapy in Bladder Cancer - Christopher Wallis & Zachary Klaassen
Pembrolizumab Alone or Combined With Chemotherapy vs Chemotherapy As First-Line Therapy for Advanced Urothelial Carcinoma in the KEYNOTE-361 Trial Journal Club – Christopher Wallis & Zachary Klaassen
CheckMate 274 Trial of Adjuvant Nivolumab vs Placebo in Patients Who Underwent Radical Surgery for High-Risk Muscle-Invasive Urothelial Carcinoma, Journal Club - Christopher Wallis & Zachary Klaassen
The Role of Risk-Stratified Neoadjuvant Chemotherapy in Patients with Muscle-Invasive Bladder Cancer Who Are Undergoing Radical Cystectomy - Arlene O. Siefker-Radtke and Shilpa Gupta
Overall Response Rate After Immune-Checkpoint Inhibitor Initiation and Post-ICI PFS in Patients With Advanced Urothelial Carcinoma - Dimitrios Makrakis
Outcomes Between Patients With and Without Prior Intravesical BCG, Who Received Immune Checkpoint Inhibitors for Advanced Urothelial Carcinoma - Rafee Talukder & Petros Grivas
Antibody-Drug Conjugates in Advanced Urothelial Cancer: Clinical Perspective - Scott Tagawa
Final Analysis of the ATLANTIS Rucaparib Arm - Simon Crabb
Practice Changing Publications in Urothelial Carcinoma - Deborah Kaye
Treatment Strategies in Advanced Urothelial Carcinoma - Stephen Boorjian
The Future of Adjuvant and Neoadjuvant Therapy for Patients with Muscle-Invasive Bladder Cancer - Tracy Rose
Clinical Outcomes With Anti-PD(L)1 Immune Checkpoint Inhibitors in Patients With Advanced Urothelial Carcinoma – Dimitrios Makrakis
Bladder Cancer Advocacy Network's (BCAN) Young Investigator Award Program - Elizabeth Plimack
Biomarkers and Next Generation Sequencing in Advanced Bladder Cancer - Noah Hahn
Cisplatin-Related Immunomodulation and Efficacy with Atezolizumab + Cisplatin Versus Carboplatin-Based Chemotherapy in Metastatic Urothelial Cancer - Matthew Galsky
Implications for Genetic Testing in Urothelial Cancer - Guru Sonpavde & Maria Carlo
Sacituzumab Govitecan in Patients With Metastatic Urothelial Carcinoma, Progressing After Platinum-Based Chemotherapy and Checkpoint Inhibitors: TROPHY-U-01 Journal Club – Christopher Wallis & Zachary Klaassen
Neoadjuvant Atezolizumab with Gemcitabine and Cisplatin in Patients with Muscle-Invasive Bladder Cancer - Samuel A. Funt
Durability and Long Term Outcome of Enfortumab Vedotin + Pembrolizumab in the EV-103 Study in Cisplatin-Ineligible Locally Advanced or Metastatic Urothelial Carcinoma – Terence W. Friedlander
Updated Results from EV-201 Cohort 2 - Enfortumab Vedotin Is A Potential Non-Platinum Option for Cisplatin-Ineligible Patients Following Anti-PD-1/L1 Treatment - Bradley McGregor
Advances in the Treatment of Metastatic Urothelial Cancer - Matthew Galsky
Intersection of Biology and Clinical Characteristics Towards Personalized Sequential Treatments for MIBC - Andrea Necchi and Ewan Gibb
TROPHY-U-01 Results Lead to Accelerated Approval of Sacituzumab Govitecan (Trodelvy) for Pretreated Metastatic Urothelial Carcinoma - Scott Tagawa
Practical Considerations for Administering Avelumab Maintenance in Clinical Practice - Petros Grivas and Neeraj Agarwal
Voluntary Withdrawal In The US of Durvalumab and of Atezolizumab in Metastatic Urothelial Carcinoma - Petros Grivas
Characterization of The Genomic Landscape of Post-Neoadjuvant Chemotherapy in MIBC Patients- Andrew Lenis
Metastatic and Muscle-Invasive Bladder Cancer European Association of Urology (EAU) Guidelines - J. Alfred Witjes
Molecular Changes Associated with Treatment Response in Muscle-Invasive Bladder Cancer Patients Treated with Cisplatin-Based Chemotherapy - Lars Dyrskjøt
Two-year JAVELIN Solid Tumor Data Phase 1 Final Results - Andrea Apolo
Comparing Nab-Paclitaxel and Paclitaxel in Platinum-Refractory Bladder Cancer - Srikala Sridhar
Implications for Reducing Disparities in Muscle-Invasive Bladder Cancer - Samuel Washington III
Guidelines for Advanced Urothelial Carcinoma in First-line Treatment for Patients Ineligible or Unfit for Cisplatin - Michiel S. Van der Heijden
Evaluating Treatments in Advanced Urothelial Carcinoma - Guru Sonpavde
Association Between Clinical Outcomes and Exploratory Biomarkers in the JAVELIN Bladder 100 Trial, Advanced Urothelial Carcinoma - Srikala Sridhar
ESMO 2020: The TROPHY-U-01 Study- Sacituzumab Govitecan for Advanced Urothelial Carcinoma - Petros Grivas
ESMO 2020: Combination Therapies in Locally Advanced or Metastatic Urothelial Carcinoma Bladder Cancer - Josh Meeks
Current Treatment Approaches in Advanced Urothelial Carcinoma - Shilpa Gupta
The Dynamic Advancements in Personalized Treatments for Metastatic Urothelial Cancer - Andrea Apolo
Prolonging Overall Survival in Patients with Muscle-Invasive Bladder Cancer - Petros Grivas
Treatment Approach: Case Study in Aggressiveness Metastatic Urothelial Carcinoma - Makarand Khochikar
Advancements in Treatments for Metastatic Urothelial Carcinoma (mUC) - Petros Grivas
JAVELIN Bladder 100: Results of First-line Maintenance Therapy Plus Best Supportive Care Demonstrates Significant Prolonged OS in Advanced Urothelial Cancer - Cora Sternberg
Assessing the Potential Cost-Effectiveness of the Addition of Atezolizumab to First-Line Platinum Chemotherapy in Advanced Urothelial Carcinoma - Ali Khaki
Progress in Bladder Cancer Research - Bishoy Faltas
IMvigor010 Primary Analysis from a Phase III Randomized Study of Adjuvant Atezolizumab versus Observation in High-Risk Muscle-Invasive Urothelial Carcinoma - Thomas Powles & Matthew Galsky
JAVELIN Bladder 100: Avelumab for Previously Untreated Locally Advanced or Metastatic Urothelial Carcinoma - Thomas Powles
Controversial and Complex Cases in Urothelial Cancer - Srikala Sridhar
The Impact of Molecular Subtyping and Immune Infiltration on Pathological Response and Outcome Following Neoadjuvant Pembrolizumab in MIBC - Andrea Necchi
The Landscape of Advanced Bladder Cancer: A Review of the Last 30-Years - Cora Sternberg
Enfortumab Vedotin for Advanced Urothelial Carcinoma - Jonathan Rosenberg
Updates on Bladder Cancer Clinical Trials ASCO GU 2020 - Matthew Galsky
Recent Advances in the Treatment of Metastatic Urothelial Cancer - Petros Grivas
Treatments in Development for Muscle-invasive Bladder Cancer - Min Yuen Teo
Advanced Bladder Cancer Clinic: Are you Ready? - Neal Shore
Immunotherapy and Chemotherapy Use in Patients with Metastatic Bladder Cancer - Ronac Mamtani and Ravi Parikh
Circulating Tumor DNA in Urothelial Cancer - Interview with Bishoy Faltas
Upper Tract Urothelial Carcinoma Has a Luminal-Papillary T-cell Depleted Contexture and Activated FGFR3 Signaling - Bishoy Faltas
Fibroblast Growth Factor Receptor 3 Alterations and Response to PD-1/PD-L1 Blockade in Patients with Metastatic Urothelial Cancer - Matt Galsky
Antibody Drug Conjugates for the Treatment of Metastatic Urothelial Carcinoma - Petros Grivas
Erdafitinib Treatment in Metastatic Urothelial Carcinoma - Petros Grivas
Biomarker Testing in Metastatic Urothelial Carcinoma - Petros Grivas
The Performance Status and Response to Immune Checkpoint Inhibition in Patients with Advanced Urothelial Carcinoma - Ali Khaki
Results from CALGB 90601 in Metastatic Urothelial Carcinoma - Jonathan Rosenberg
Novel New Approaches in the Neoadjuvant Disease Setting for Bladder Cancer - Petros Grivas
Urinary Diversion after Radical Cystectomy - Morgan Roupret
Assessing and Managing Toxicities with Immune Checkpoint Inhibitors - Brenda Martone
Erdafitinib in Bladder Cancer - Arjun Balar
Implications of Clinical Response Following Neoadjuvant Chemotherapy - Seth Lerner
Treating Advanced Bladder Cancer - Petros Grivas
Optimizing Treatment Outcomes in Muscle Invasive Bladder Cancer (MIBC) - Wassim Kassouf
Bladder Sparing Strategies for Urothelial Cancer - Jason Efstathiou
Neoadjuvant Treatment in Muscle Invasive Bladder Cancer- Andrea Necchi
Antibody-drug Conjugate (ADC) Sacituzumab Govitecan in Metastatic UroThelial Carcinoma - Scott Tagawa
Joshua J. Meeks on SWOG 1806 Study
Combination Approaches with Immune-Checkpoint Blockade in Bladder Cancer - Matthew Galsky
Immune Checkpoint Inhibitors Trials in Urothelial Cancer: Recent Updates and Future Outlook - Andrea Apolo
A Conversation on Immuno-Oncology in Bladder Cancer - Petros Grivas
Update on Immunotherapy Advances in Renal and Bladder Cancer - Cora Sternberg
Advances in Bladder Cancer Beyond Immunotherapy and Checkpoint Inhibitors - Evan Yu
Atezolizumab in Metastatic Urothelial Carcinoma Outside Clinical Trials -Pedro Barata
Updates on Health-Related Quality-of-Life (HRQoL) analyses in GU Oncology - Cora Sternberg
The State of Advanced Bladder Cancer - New Data from AACR 2018 - Interview with Arjun Balar

PCF 2021 Videos

email news signup